800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
The analyst writes that clinical trials have shown that Anktiva delivers high complete response rates and long-term disease control, indicating its potential to enhance patient outcomes. This could minimize the need for radical surgeries while broadening the range of available immuno-oncology treatments.EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectious diseases.
EF Hutton已經開始對ImmunityBio Inc.（納斯達克:IBRX）進行覆蓋，這是一家垂直一體化的生物技術公司，致力於開發治療和疫苗，以增強自然免疫系統，用於治療癌症和傳染病。
In April this year, the FDA approved ImmunityBio's Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
今年4月，FDA批准了ImmunityBio的Anktiva（N-803，或nogapendekin alfa inbakicept-pmln）與卡介苗（BCG）聯合用於對BCG無效的非肌肉侵襲性膀胱癌患者，存在原位癌，有或無乳頭狀腫瘤。
The analyst writes, "Anktiva has the potential to revolutionize cancer immunotherapy by enhancing the efficacy of immune-based treatments, particularly in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)."
分析師寫道，「Anktiva有潛力通過增強基於免疫的治療的功效，特別是對於BCG無效的非肌肉侵襲性膀胱癌（NMIBC），來改革癌症免疫療法。」
The analyst writes that clinical trials have shown that Anktiva delivers high complete response rates and long-term disease control, indicating its potential to enhance patient outcomes. This could minimize the need for radical surgeries while broadening the range of available immuno-oncology treatments.
分析師寫道，臨床試驗顯示，Anktiva提供高完全緩解率和長期疾病控制，這表明其增強患者預後的潛力。這可能減少對激進手術的需求，同時擴大可用的免疫腫瘤治療範圍。
The analyst initiates with a Buy rating and a price target of $30, an astonishing upside of over 800%.
該分析師發起了買入評級，目標股價爲30美元，超過800%的驚人上漲空間。
EF Hutton writes that Anktiva can potentially broaden the effectiveness of cancer immunotherapy, especially when paired with checkpoint inhibitors. It boosts the activity of natural killer (NK) and CD8+ T cells, which may help "heat" cold tumors, making them more receptive to immune checkpoint therapies.
EF Hutton寫道，Anktiva潛在地可以拓寬癌症免疫療法的有效性，尤其是當與檢查點抑制劑配對時。它增強了自然殺傷細胞（NK）和CD8+T細胞的活性，可能有助於使「冷」腫瘤變得更容易接受免疫檢查點療法。
Last month, ImmunityBio revealed results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer (NSCLC) treated with checkpoint inhibitors (CPI).
上個月，ImmunityBio公佈了其QUILt 3.055試驗結果，顯示接受檢測點抑制劑（CPI）治療的晚期非小細胞肺癌（NSCLC）患者的長期延長生存時間，可達14個月至五年。
The phase 2b study of ANKTIVA in combination with checkpoint inhibitors such as Merck & Co Inc's (NYSE:MRK) Keytruda or Bristol Myer Squibb & Co's (NYSE:BMY) Opdivo in multiple tumor types, including NSCLC who failed CPI, showed long-term overall survival of 57% (49/86) and 34% (29/86) at 12 and 18 months, respectively, exceeding the current standard of care.
在ANKTIVA與默克公司（紐交所:MRK）的Keytruda或百時美施貴寶公司（紐交所:BMY）的Opdivo等檢查點抑制劑聯合用於包括失敗CPI的多種腫瘤類型，包括NSCLC的第20億階段研究顯示，長期總生存率分別爲57%（49/86）和34%（29/86），在12個月和18個月時超過當前的標準治療。
Price Action: IBRX stock is down 1.58% at $3.43 at the last check Wednesday.
價格走勢：IBRX股票在上週三最後一次檢查時下跌1.58%，報3.43美元。
- Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices.
- 波士頓科學第三季收益：營業收入和每股收益超過預期，受益於心臟設備需求強勁，提升了全年預測。
譯文內容由第三人軟體翻譯。
